Secukinumab attenuates neuroinflammation and neurobehavior defect via PKCβ/ERK/NF-κB pathway in a rat model of GMH

Shengpeng Liu,Shuixiang Deng,Yan Ding,Jerry J. Flores, Xiaoli Zhang, Xiaojing Jia,Xiao Hu, Jun Peng,Gang Zuo,John H. Zhang,Ye Gong,Jiping Tang

Experimental Neurology（2022）

引用 1|浏览9

暂无评分

摘要

•Intranasal administration of IL-17A antibody Secukinumab at 1 h after GMH significantly improved long- and short-term neurological outcomes; reduced the expression of IL-1β, MPO and Iba-1 near the area of hematoma.•Secukinumab suppressed the expression of inflammatory via PKCβ/ERK/NF-κB pathway

查看译文

关键词

Secukinumab,Neurobehavior,Neuroinflammation,IL-17A,GMH

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要